Pathways of care and resource utilization in a national cohort of patients with transfusion‐acquired hepatitis C
- 19 September 2005
- journal article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 12 (6) , 618-626
- https://doi.org/10.1111/j.1365-2893.2005.00654.x
Abstract
Summary. The Hepatitis C Strategy and Action Plan for England recommend that all individuals testing positive for hepatitis C virus (HCV) should be referred to a specialist centre for assessment and care. One key aim is to reduce the number of people progressing to liver disease and therefore reduce the associated costs. The aims of this paper are to describe the care pathways and evaluate resource utilization in a cohort of 826 patients with transfusion‐acquired hepatitis C enrolled in the HCV national register. We reviewed data extracted from patient notes to establish pathways of care since HCV‐positive diagnosis through to May 2002, and to document all treatment, liver biopsy and hospital usage for each patient. Type of care was classified into specialist‐interest in HCV‐related care, other‐hospital care or general practitioner (GP)‐led care. Over 70% of patients were referred to specialist care following HCV diagnosis. Patients who were older or who had normal liver function were less likely to be referred to specialist‐care. Between first diagnosis and May 2002, no patients were referred from GP to specialist‐care. Less than half of this cohort had undergone liver biopsy and only 18% had been treated. Younger patients and those with abnormal liver function were more likely to have undergone liver biopsy and to have received treatment. Analysis of care histories of patients with transfusion‐acquired hepatitis C suggest that changes are needed in the care and management of patients with HCV infection, if the recommendations of the HCV strategy and action plan are to be fully implemented.Keywords
This publication has 13 references indexed in Scilit:
- Survival after transfusion as assessed in a large multistate US cohortTransfusion, 2004
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- The contribution of transfusion to HCV infection in EnglandEpidemiology and Infection, 2002
- Clinical course of hepatitis C virus during the first decade of infection: cohort studyBMJ, 2002
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialPublished by Elsevier ,2001
- The HCV National Register: towards informing the natural history of hepatitis C infection in the UKJournal of Viral Hepatitis, 2000
- Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review.Health Technology Assessment, 2000
- Global surveillance and control of hepatitis CJournal of Viral Hepatitis, 1999
- Hepatitis CThe Lancet, 1998
- Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patientsGastroenterology, 1997